Jun 20 |
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
|
Jun 14 |
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
|
May 29 |
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
|
May 16 |
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
|
May 15 |
Kodiak Sciences GAAP EPS of -$0.82 beats by $0.21
|
May 15 |
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
|
May 14 |
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
|
May 13 |
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
|
May 2 |
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
|
Apr 11 |
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
|